ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
ImmunityBio 完成了足夠生產 170,000 劑 ANKTIVA 的 GMP 藥物製造
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
Coupled with a recent announcement of BCG availability in partnership with the Serum Institute of India (SII), ImmunityBio has large-scale inventory and capacity for BCG
ANKTIVA 藥物物質完成併發布了兩年的儲存穩定性數據，足以容納 170,000 劑 ANKTIVA 產品
ImmunityBio位於紐約敦刻爾克的40萬平方英尺的GMP灌裝廠有望在12-18個月內完工，每年可生產100萬瓶藥瓶
加上最近宣佈與印度血清研究所（SII）合作推出卡介苗，ImmunityBio擁有大量的卡介苗庫存和產能
ImmunityBio, Inc. ((IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for "fill finish" (filling vials and finishing packaging), sufficient for 170,000 doses of 400mcg ANKTIVA...
ImmunityBio公司（IBRX）今天宣佈，該藥物物質...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。